STOCK TITAN

Journey Medical Corp - DERM STOCK NEWS

Welcome to our dedicated news page for Journey Medical (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Journey Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Journey Medical's position in the market.

Rhea-AI Summary
Journey Medical Corporation will release its third quarter 2023 financial results on November 7, 2023. The company will host a conference call and audio webcast at 4:30 p.m. ET on the same day. Interested parties can join the call by dialing 1-866-777-2509 (domestic) or 1-412-317-5413 (international). A live audio webcast will also be available on Journey Medical's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
-
Rhea-AI Summary
Journey Medical announces data from a comparative bioavailability study of DFD-29 vs. Solodyn for the treatment of rosacea
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
-
Rhea-AI Summary
Journey Medical enters exclusive license agreement with Maruho Co., Ltd. for Qbrexza in multiple territories
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.68%
Tags
none
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a 41% increase in total net revenues to $17.2 million in Q2 2023, and positive topline results from two Phase 3 clinical trials evaluating DFD-29 for papulopustular rosacea treatment. The company plans to submit an NDA to the FDA for DFD-29 in H2 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
-
Rhea-AI Summary
DERM: Journey Medical Corporation to Discuss Positive Topline Clinical Data and Financial Results in Upcoming Conference Call on August 8, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.01%
Tags
-
Rhea-AI Summary
Journey Medical Corporation will release its second quarter 2023 financial results during the week of August 7, 2023. The company will also host a conference call to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.68%
Tags
Journey Medical Corp

Nasdaq:DERM

DERM Rankings

DERM Stock Data

88.10M
8.25M
29.91%
9.72%
0.74%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States
Scottsdale